Michael Holinstat

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. pmc Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis
    Michael Holinstat
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Arterioscler Thromb Vasc Biol 31:435-42. 2011
  2. pmc Newer agents in antiplatelet therapy: a review
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Blood Med 3:33-42. 2012
  3. pmc 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity
    J Yeung
    Michael Holinstat, Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, 1020 Locust Street, Suite 394, Jefferson Alumni Hall, Philadelphia, PA, USA, Tel 1 215 955 6121, Fax 1 215 955 9170, E mail
    Thromb Haemost 110:569-81. 2013
  4. pmc Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Pharmacol 81:420-30. 2012
  5. pmc Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race
    Leonard C Edelstein
    Cardeza Foundation for Hematologic Research, Sidney Kimmel Medical College, Philadelphia, PA
    Blood 124:3450-8. 2014
  6. pmc Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects
    John H Cleator
    Department of Medicine and Division of Cardiovascular Medicine J H C, Department of Pharmacology J H C, M T D, M H, N E C, W J H, H E H, and Department of Biostatistics Y S, F E H, Vanderbilt University Medical Center, Nashville, Tennessee and Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, Pennsylvania M H
    J Pharmacol Exp Ther 351:33-43. 2014
  7. pmc Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
    Blood 124:2271-9. 2014
  8. pmc Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c
    Leonard C Edelstein
    The Cardeza Foundation for Hematologic Research and Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Nat Med 19:1609-16. 2013
  9. pmc Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and gq signaling axis
    Benjamin E Tourdot
    From the Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA
    Arterioscler Thromb Vasc Biol 34:2644-50. 2014
  10. pmc MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression
    Raul Teruel-Montoya
    Cardeza Foundation for Hematologic Research and Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 9:e102259. 2014

Collaborators

  • Olivier Boutaud
  • Paul F Bray
  • Anton Simeonov
  • Jing Fei Dong
  • Jennifer Yeung
  • Leonard C Edelstein
  • Benjamin E Tourdot
  • Raul Teruel-Montoya
  • Xianguo Kong
  • Lin Ma
  • Steven E McKenzie
  • Chad A Shaw
  • John H Cleator
  • Edward S Chen
  • Lukas M Simon
  • Joanne Vesci
  • Theodore R Holman
  • Ajit Jadhav
  • David J Maloney
  • J Yeung
  • Pilar Fernandez-Perez
  • Marvin Nieman
  • Jin Ren
  • Willie J Hudson
  • Shaji Abraham
  • Diane K Luci
  • Katrin Niisuke
  • Matthew T Duvernay
  • Heidi E Hamm
  • Shaun Coughlin
  • Frank E Harrell
  • Nancy E Colowick
  • Satya P Kunapuli
  • Christopher J Smyrniotis
  • Cory R Lindsay
  • Stanley Conaway
  • Yanna Song
  • Narla Mohandas
  • T R Holman
  • D J Maloney
  • David E Cohen
  • Srikanth Nagalla
  • P Fernandez-Perez
  • J Vesci
  • Chad Shaw
  • G Rai
  • M Stolla
  • Angela Bergeron
  • A Jadhav
  • Raúl Teruel Montoya
  • P L Apopa
  • Patrick L Apopa
  • Ganesha Rai
  • Victor Kenyon

Detail Information

Publications12

  1. pmc Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis
    Michael Holinstat
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
    Arterioscler Thromb Vasc Biol 31:435-42. 2011
    ..We evaluated signaling via the human platelet thrombin receptors, protease-activated receptor (PAR) 1 and PAR4, to the activation of cPLA(2α), which provides a substrate for the biosynthesis of TxA(2) and 12-HETE...
  2. pmc Newer agents in antiplatelet therapy: a review
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Blood Med 3:33-42. 2012
    ....
  3. pmc 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity
    J Yeung
    Michael Holinstat, Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, 1020 Locust Street, Suite 394, Jefferson Alumni Hall, Philadelphia, PA, USA, Tel 1 215 955 6121, Fax 1 215 955 9170, E mail
    Thromb Haemost 110:569-81. 2013
    ..Furthermore, the data presented here provide a basis for potentially targeting 12-LOX as a means to attenuate unwanted platelet activation and clot formation. ..
  4. pmc Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Mol Pharmacol 81:420-30. 2012
    ..These studies support an essential role for PKC downstream of 12-LOX activation in human platelets and suggest 12-LOX as a possible target for antiplatelet therapy...
  5. pmc Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race
    Leonard C Edelstein
    Cardeza Foundation for Hematologic Research, Sidney Kimmel Medical College, Philadelphia, PA
    Blood 124:3450-8. 2014
    ..These findings may have an important pharmacogenetic effect on the development of new PAR antagonists...
  6. pmc Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects
    John H Cleator
    Department of Medicine and Division of Cardiovascular Medicine J H C, Department of Pharmacology J H C, M T D, M H, N E C, W J H, H E H, and Department of Biostatistics Y S, F E H, Vanderbilt University Medical Center, Nashville, Tennessee and Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, Pennsylvania M H
    J Pharmacol Exp Ther 351:33-43. 2014
    ..The racial difference in platelet function in T2DM is a novel finding, which may lead to differences in treatment as well as new targets for antiplatelet therapy. ..
  7. pmc Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation
    Jennifer Yeung
    Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
    Blood 124:2271-9. 2014
    ..These results support an essential role for 12-LOX in regulating FcγRIIa-mediated platelet function and identifies 12-LOX as a potential therapeutic target to limit immune-mediated thrombosis. ..
  8. pmc Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c
    Leonard C Edelstein
    The Cardeza Foundation for Hematologic Research and Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Nat Med 19:1609-16. 2013
    ....
  9. pmc Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and gq signaling axis
    Benjamin E Tourdot
    From the Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA
    Arterioscler Thromb Vasc Biol 34:2644-50. 2014
    ..Determining where in the signaling cascade these racial differences emerge will aid in understanding why individuals of differing racial ancestry may possess an inherent difference in their responsiveness to antiplatelet therapies...
  10. pmc MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression
    Raul Teruel-Montoya
    Cardeza Foundation for Hematologic Research and Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 9:e102259. 2014
    ....
  11. pmc 12-lipoxygenase: a potential target for novel anti-platelet therapeutics
    Jennifer Yeung
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA
    Cardiovasc Hematol Agents Med Chem 9:154-64. 2011
    ....
  12. pmc Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation
    Michael Holinstat
    Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA
    J Thromb Thrombolysis 35:209-22. 2013
    ..Hence, our data are the first to show that exposure to bivalirudin increased P-selectin expression with certain conditions demonstrating that bivalirudin can increase inherent platelet activity...